^
Association details:
Biomarker:IDH1 mutation
Cancer:Glioma
Regimen:PCV (lomustine + Matulane (procarbazine hydrochloride) + vincristine)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Source:
Title:

Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802.

Excerpt:
Both the IDHmut/non-co-deleted and IDHmut/co-deleted subgroups were significantly correlated with longer PFS (HR = 0.32; p = 0.003; HR = 0.13; p < 0.001) and OS (HR = 0.38; p = 0.013; HR = 0.21; p = 0.029) in the RT plus PCV arm, respectively.
DOI:
10.1200/JCO.2019.37
Trial ID: